DNB Asset Management AS Purchases 10,148 Shares of Insulet Corporation $PODD

DNB Asset Management AS lifted its position in Insulet Corporation (NASDAQ:PODD) by 21.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,161 shares of the medical instruments supplier’s stock after buying an additional 10,148 shares during the period. DNB Asset Management AS’s holdings in Insulet were worth $16,532,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in PODD. NewEdge Advisors LLC increased its holdings in Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares in the last quarter. Cresset Asset Management LLC increased its holdings in Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 177 shares in the last quarter. Cerity Partners LLC increased its holdings in Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after purchasing an additional 7,030 shares in the last quarter. Sei Investments Co. increased its holdings in Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after purchasing an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after purchasing an additional 791 shares in the last quarter.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.36% of the company’s stock.

Insulet Trading Down 0.8%

Insulet stock opened at $147.46 on Friday. Insulet Corporation has a 52 week low of $145.59 and a 52 week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a market capitalization of $10.21 billion, a P/E ratio of 34.29, a PEG ratio of 1.20 and a beta of 1.20. The stock has a 50-day simple moving average of $199.93 and a 200 day simple moving average of $256.98.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the company posted $1.02 earnings per share. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts expect that Insulet Corporation will post 6.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. The Goldman Sachs Group set a $237.00 target price on Insulet in a report on Thursday, May 7th. Leerink Partners lowered their target price on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Raymond James Financial lowered their target price on Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Finally, Truist Financial reduced their price objective on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Nineteen equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $257.09.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.